FDA Grants Orphan Status for Halo’s DMD Drug Candidate

Halo Therapeutics, the do-it-yourself biotech founded by two American families with children diagnosed with Duchenne’s Muscular Dystrophy (DMD), has received orphan drug status for HT-100 for the treatment of DMD. Halo licensed HT-100 from Collard and plans to launch a clinical trial this year with support from nonprofits and patients groups. The candidate drug is thought to promote healthy muscle fiber regeneration and may broadly benefit other neuromuscular diseases including ALS.

Click here to read more.

Share this: